This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Galleon's Biotech Stock Holdings: BioBuzz

NEW YORK, NY ( TheStreet) -- Galleon Group may be forced to sell its extensive biotech holdings as investors in the hedge fund seek to pull out their money following the arrest this week of founder Raj Rajaratnam on charges of alleged insider trading.

Galleon owns a long list of biotech stocks, but many of the fund's positions aren't particularly large, according to the fund's 13-F for the September quarter, filed with the Securities and Exchange Commission. Some of its holdings are in highly liquid stocks, so any selling that might occur could be easily sopped up by the market.

OSI Pharmaceuticals (OSIP), OncoGenex Pharmaceuticals (OGXI - Get Report), Medivation (MDVN - Get Report), Orexigen Therapeutics (OREX - Get Report) and Biogen Idec (BIIB) are among the larger biotech stock positions held by Galleon, according to its SEC filing.

The fund holds numerous other smaller biotech holdings, including Acorda Therapeutics (ACOR), Dendreon (DNDN), Rigel Pharmaceuticals (RIGL - Get Report), Optimer Pharmaceuticals (OPTR), Amylin Pharmaceuticals (AMLN) and Alexion Pharmaceuticals (ALXN).

The biotech sector is underperforming the market today, with Galleon holding Oncogenex down 8%. But then, Medivation, another of the fund's holdings, is up 2% today.

-- Reported by Adam Feuerstein in Boston
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OPTR $0.00 0.00%
DNDN $0.06 -6.02%
MDVN $41.30 0.00%
OGXI $2.11 0.00%
OREX $2.53 0.00%


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs